Business & Industry News Channel

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease

AstraZenecaAstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

Read more...

Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices

RocheFor the sixth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry. This places Roche amongst the top 10 percent of companies across all surveyed industries.

Read more...

GSK joins with research councils in UK and South Africa to tackle non-communicable diseases

GlaxoSmithKlineGSK has announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK's Africa NCD Open Lab initiative.

Read more...

Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies

BayerData presented at the European Respiratory Society (ERS) Congress today confirm the safety profile and the sustained efficacy of Adempas® (riociguat) over at least two years of treatment in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and in patients with pulmonary arterial hypertension (PAH).

Read more...

AstraZeneca and Redx Pharma agree research collaboration

AstraZenecaAstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival. The research will complement AstraZeneca's strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.

Read more...

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

NovartisAt the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done[1],[6].

Read more...

New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients

AstraZenecaAstraZeneca has announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]